Indication
Tislelizumab
7 clinical trials
3 products
4 drugs
Clinical trial
Retrospective Study of Tislelizumab Combined With Chemotherapy in First-line Treatment of HER2-negative Advanced Gastric CancerStatus: Active (not recruiting), Estimated PCD: 2022-11-01
Product
TislelizumabClinical trial
Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer (STARS-RC03)Status: Active (not recruiting), Estimated PCD: 2023-10-18
Product
SintilimabClinical trial
Phase II Study of Moderate-dose Hypofractionated Radiotherapy Combined With Tislelizumab for Hepatocellular Carcinoma With Diffuse Tumor Thrombosis Involved Both Left and Right LiverStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
XELOX and Bevacizumab in Combination With Tislelizumab for First-Line Treatment of Patients With MSS/pMMR RAS-mutated Metastatic Colorectal Cancer (mCRC): A Single-arm, Phase II Study.Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Lenvatinib Combined With Tislelizumab and TACE Applied as Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma With High Risk of Recurrence: Study Protocol of a Monocenter, Single-arm, Open Label Clincal TrailStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract CancerStatus: Not yet recruiting, Estimated PCD: 2024-06-01
Drug
AdebrelimabDrug
TiragolumabDrug
PD-1 antibodyClinical trial
Multicenter, Single-arm, Open-label Phase II Clinical Study of Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal CancerStatus: Not yet recruiting, Estimated PCD: 2024-12-31